BACKGROUND: The molecular pathogenesis of clear cell endometrial cancer (CCEC), a tumor type with a relatively unfavorable prognosis, is not well defined. We searched exome-wide for novel somatically mutated genes in CCEC and assessed the mutational spectrum of known and candidate driver genes in a large cohort of cases. METHODS: We conducted whole exome sequencing of paired tumor-normal DNAs from 16 cases of CCEC (12 CCECs and the CCEC components of 4 mixed histology tumors). Twenty-two genesof-interest were Sanger-sequenced from another 47 cases of CCEC. Microsatellite instability (MSI) and microsatellite stability (MSS) were determined by genotyping 5 mononucleotide repeats. Results: Two tumor exomes had relatively high mutational loads and MSI. The other 14 tumor exomes were MSS and had 236 validated nonsynonymous or splice junction somatic mutations among 222 protein-encoding genes. Among the 63 cases of CCEC in this study, we identified frequent somatic mutations in TP53 (39.7%), PIK3CA (23.8%), PIK3R1 (15.9%), ARID1A (15.9%), PPP2R1A (15.9%), SPOP (14.3%), and TAF1 (9.5%), as well as MSI (11.3%). Five of 8 mutations in TAF1, a gene with no known role in CCEC, localized to the putative histone acetyltransferase domain and included 2 recurrently mutated residues. Based on patterns of MSI and mutations in 7 genes, CCEC subsets molecularly resembled serous endometrial cancer (SEC) or endometrioid endometrial cancer (EEC). CONCLUSION: Our findings demonstrate molecular similarities between CCEC and SEC and EEC and implicate TAF1 as a novel candidate CCEC driver gene.
INTRODUCTION
Worldwide, endometrial carcinomas (ECs) account for approximately 76,000 deaths annually. 1 They can be categorized into several histological subtypes, including endometrioid endometrial cancer (EEC), serous endometrial cancer (SEC), and clear cell endometrial cancer (CCEC). EECs represent approximately 80% of all newly diagnosed ECs. They are generally low-grade tumors and are usually diagnosed at an early clinical stage. 2 The 5-year relative survival rate for patients with EEC is favorable overall (91%), 3 although patients with high-grade EEC have a less favorable prognosis. SEC and CCEC account for 3%-10.5% and 1%-6% of newly diagnosed cases of EC, respectively. [4] [5] [6] In contrast to most cases of EEC, SEC and CCEC tend to be diagnosed at late clinical stages and are, by definition, high-grade tumors. The 5-year relative survival rates for SEC and CCEC are 45% and 65%, respectively, compared with 91% for EEC. 3 The mutational landscape of SEC and EEC exomes has been reported by several groups, [7] [8] [9] [10] [11] [12] [13] and an integrated genomic analysis of SECs and EECs has been conducted by The Cancer Genome Atlas (TCGA). 12 In contrast, the molecular etiology of CCEC remains poorly understood. One primary CCEC has been exome-sequenced, but the mutational repertoire was not reported. 13 Other studies have Sanger-sequenced limited numbers of genes in relatively small cohorts of CCEC patients. 7, [14] [15] [16] [17] [18] The most frequently mutated cancer genes reported in CCEC thus far are TP53, PPP2R1A, PIK3R1, SPOP, PIK3CA, ARID1A, and FBXW7 7, [14] [15] [16] [17] [18] ; 11%-14% of CCECs exhibit microsatellite instability (MSI).
14, 18 The presence of both TP53 and PTEN mutations in CCEC led to speculation of an overlapping molecular etiology with SEC and EEC, 14 an idea that has gained support by a subsequent study of several additional genes 17 ; however, these observations were made in small cohorts (14 and 16 cases, respectively). 14, 17 In this study, we used a combination of exome sequencing and targeted Sanger sequencing to interrogate the mutational landscape of a relatively large series of CCECs. Our findings implicate TAF1 as a novel candidate driver gene in a subset of cases. Moreover, we demonstrate that a substantial number of CCECs molecularly resemble either SEC or EEC.
MATERIALS AND METHODS

Clinical Specimens
All tumor specimens were fresh-frozen tissues resected before treatment from patients who were clinically diagnosed with CCEC (n 5 59) or EC with clear cell components (n 5 4). The National Institutes of Health Office of Human Subjects Research Protections determined that this research was not human subject research per the Common Rule (45 CFR 46), therefore Institutional Review Board (IRB) approval was not required for sequencing of these samples. Providing institutions received appropriate IRB approval. Our study included 59 cases of CCEC and 4 cases with a histopathological diagnosis of more than 1 histology for which only the CCEC components were analyzed.
Genomic DNA Extraction
The neoplastic cellularity of tumors is provided in Supporting Table 1 . DNA isolation from regions of tumor tissue and identity testing of tumor-normal DNA pairs to confirm origination from the same patient has been described elsewhere. 7, 19, 20 Before whole exome sequencing, tumor-normal DNAs were further purified by way of phenol-chloroform extraction. Four non-tumor DNAs (32N, 59N, 64N , and 82N) underwent whole genome amplification using the REPLI-g amplification service (Qiagen) before exome capture; corresponding unamplified DNAs were used for somatic mutation validation.
Library Construction and Sequencing
Sequencing libraries of 16 paired tumor-normal DNAs were generated using Illumina Truseq (13 pairs) or Agilent SureSelect (3 pairs) capture kits (Supporting Table 2 ).
Read Mapping, Variant Calling, and Variant Filtering
Sequence reads were aligned to the National Center for Biotechnology Information's Build 36 (hg18) reference using CASAVA version 1.8.0 for initial placement followed by a banded Smith-Waterman algorithm (cross_-match, http://www.phrap.org), and variants and their associated genotypes were called with bam2mpg, filtering bases with <Q20 Phred score and using the score_variant option, as described previously. 7, 21 VarSifter 22 was used to identify coding and splice somatic variants with an MPG score 10 in the normal sample, an MPV score 10 in the tumor sample, and at least 5 reads covering the site in each sample. Private single-nucleotide polymorphisms (SNPs) detected in any normal sample, probable false-positive variants consistent with sequencing artifacts or misaligned reads as determined by manual data curation, and variants annotated as nonclinical SNPs in dbSNP v135 were filtered out.
Polymerase Chain Reaction Amplification and Sanger Sequencing
Primer sequences and polymerase chain reaction conditions are available on request. Sanger sequencing and analysis were performed as described previously. 7 
Predicting Functional Significance of Missense Mutations
Nonsynonymous missense mutations were evaluated using SIFT (May 2011 release) (http://sift.jcvi.org), Mutation Assessor (Release 2) (http://mutationassessor. org), and PolyPhen-2 (http://genetics.bwh.harvard.edu/ pph2/). We classified variants as likely to impact function if they were scored by 2 algorithms as "damaging" or "damaging_low confidence" (SIFT), "medium impact" or "high impact" (Mutation Assessor), or "deleterious" (PolyPhen).
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MSI Analysis
MSI analysis was performed as described previously. 7 MSI-high tumor genotypes (2 unstable mononucleotide markers) are reported here as MSI. MSI-low and MSInegative tumor genotypes are reported as microsatellite stable (MSS).
Immunoblotting
Cells were lysed in a 1% Triton X-100 buffer containing 1 mM sodium orthovanadate, 10 mM sodium fluoride, and 1 3 protease inhibitor cocktail (Roche). Protein was quantified using the Quick Start Bradford reagent (BioRad), denatured, separated by SDS-PAGE, and transferred to PVDF membranes (Turbo Transfer, Bio-Rad). TAF1 (Cell Signaling Technology, 12781) and b-actin (Sigma-Aldrich, A2228) were visualized with Clarity ECL substrate (Bio-Rad) and SuperSignal West Pico chemiluminescent substrate (Thermo Scientific), respectively.
Accession Code for Whole Exome Sequencing Data
The accession code for whole exome sequencing data is phs000967.v1.p1 (database of Genotypes and Phenotypes [dbGaP]).
RESULTS
Discovery Screen
We conducted whole exome sequencing of tumor-normal pairs from 12 cases of CCEC and the CCEC components of 4 additional cases: 2 cases of EEC with focal CCEC (T46 and T60), a mixed papillary serous and clear cell adenocarcinoma (T59), and a mixed histology tumor (T61) described as clear cell and endometrioid with squamous differentiation. Exome sequencing of the 16 paired samples resulted in a mean depth of coverage for aligned sequence reads of 753; on average, 89.3% of targeted bases had sufficient coverage and quality for variant calling (Supporting Table 2 ). After filtering, there were 1685 exonic and 24 splice junction somatic variant calls among the 16 tumors (Supporting Tables 3 and 4) . Two tumors (T61 and T77) had MSI 7 and relatively high mutational loads (662 and 472 somatic variant calls) (Supporting Table 4 ). The other 14 tumors were MSS 7 and had relatively low mutational loads (7-85 somatic variant calls) (Supporting Table 3 ). Among the 14 MSS tumors, we identified 575 somatic variants in exons (nonsynonymous and synonymous) or at splice junctions. We were able to assess 306 variants (nonsynonymous and splice junction) by Sanger sequencing; 77.1% (236 of 306) of assessed variants validated as somatic mutations (233 nonsynonymous and 3 splice junction) among 222 protein-encoding genes (Supporting Table 3 ).
Prevalence Screen
For the mutation prevalence screen, we Sanger-sequenced 22 genes-of-interest from another 47 cases of CCECs. The genes of interest reflected genes that were validated as somatically mutated in 1) at least 2 MSS CCEC exomes, 2) at least 1 MSS CCEC exome and at least 1 clear cell ovarian cancer exome, 23 and 3) known cancer genes previously implicated in CCEC (Fig. 1) . We also determined the MSI status of prevalence screen tumors. Considering all 63 tumors in the combined discovery and prevalence screens, the most frequently mutated genes of interest were TP53 (39.7%), PIK3CA (23.8%), PIK3R1 (15.9%), ARID1A (15.9%), PPP2R1A (15.9%), SPOP (14.3%), TAF1 (9.5%), FBXW7 (7.9%), and MLL3 (KMT2C) (7.9%) (Fig. 2) ; MSI was detected in 11.3% of cases. Mutations in TAF1 and MLL3 have not been reported previously in CCEC. Here, we show that TAF1 is expressed at variable levels in EC cell lines (Supporting Fig. 1 ) and was mutated in 6 of 63 (9.5%) CCECs (Fig.  2) . All 8 TAF1 mutations were missense mutations (Supporting Table 5 ). Five TAF1 mutations localized to the putative histone acetyltransferase (HAT) domain, including 2 recurrently mutated residues (arginine-843 and alanine-850) (Fig. 3) . The 3 TAF1 mutations (Val405Met, Arg1163Cys, and Arg1198Gln) that localized to regions other than the HAT domain occurred within a single tumor (T113) that has somatically mutated MSH6 and appears to be hypermutated (Fig. 2) . All 8 TAF1 mutations are predicted to impact function by at least 2 of 3 in silico algorithms (Supporting Table 5 ). For MLL3, we identified 6 mutations in 5 tumors (Fig. 2 and Supporting Table 5 ). Of the 6 MLL3 mutations, 3 were frameshifts and 3 were missense mutations (Supporting Table 5 and Fig. 3) . Each of the frameshift mutations occurred amino terminal to the SET [Su(var), Enhancer of zeste, Trithorax] domain, which is a domain commonly found among lysine methyltransferases. 24 
Comparison of the Molecular Features of CCEC to Those of SEC and EEC
We next sought to compare the molecular profiles of the 63 cases of CCEC in this study to those of SEC and EEC. Seven genes in our prevalence screen (TP53, PPP2R1A, PTEN, ARID1A, KRAS, PIK3R1 and PIK3CA) are mutated at differential frequencies between SEC and EEC: TP53 and PPP2R1A mutations are enriched in SEC, whereas PTEN, ARID1A, KRAS, PIK3R1, and PIK3CA mutations are enriched in EEC. 12, 15, 16, 25 Likewise, the rate of MSI is higher in EEC than SEC. 12, 26 We previously assessed MSI and Sanger-sequenced all 7 genes in 45 cases of SEC 7,15,16 and 5 of the 7 genes in 40 cases of EEC 7, 15, 16, 27 ; here we Sanger-sequenced TP53 and ARID1A in EEC (Supporting Table 6 ). Overall, 66.7% of CCEC cases, 82.2% of SEC cases, and 97.5% of EEC cases had at least 1 detectable alteration across the 7 genes and MSI. Next, we classified tumors according to whether they had mutations exclusively in SEC-enriched genes (group 1), exclusively in EEC-enriched genes (group 3), or in a combination of both gene sets (group 2). Whereas the majority (82.5%) of EEC cases had group 3 mutation profiles, the majority (75.5%) of SEC cases had either group 1 or group 2 mutation profiles (Supporting Fig. 2 ). By comparison, the mutation profiles of CCEC cases had an intermediate distribution to the cases of SEC and EEC (Fig. 4) , with 27.0% of cases in group 1, 19.1% in group 2, and 20.6% in group 3; another 33.3% of CCEC cases had no detectable alterations within this panel of markers.
DISCUSSION CCEC is a rare histological EC subtype that is associated with a relatively poor prognosis. A recent study of CCEC cases within the National Cancer Data Base noted 5-year overall survival rates of 74.9% for stage I, 64.3% for stage Figure 2 . Somatic mutational status of 22 genes of interest, and the MSI status, in the discovery and prevalence screen clear cell endometrial cancers (CCECs). Four tumors with heterogeneous histology for which the CCEC component was sequenced are marked with an asterisk (*). Genes and somatic mutation frequencies (% cases mutated) are shown. Somatic mutations (yellow) and MSI (gray) are indicated. Genes for which a subset of cases (23 tumors) were analyzed previously for mutations and MSI as reported elsewhere 7, 15, 16, 27 are denoted by a pound sign (#).
II, and 40.2% for stage III disease. 28 Here, we used whole exome sequencing to systematically search for somatically mutated genes in 12 cases of CCEC and in the CCEC components of 4 cases that had other coexisting histologies. Our mutation discovery screen together with targeted gene sequencing in a larger cohort of clinically diagnosed CCECs implicated TAF1, and to a lesser extent MLL3, as novel candidate driver genes of some CCECs. TAF1 encodes a subunit of the TFIID basal transcription factor complex and, although it has been nominated as a candidate driver gene in SECs, 11 to our knowledge this is the first report of somatic mutations of TAF1 in CCEC. We speculate that the frameshift mutations we uncovered in MLL3, which encodes a histone lysine . CCEC resembles both SEC and EEC based on the mutational status of 7 genes and MSI. Vertical columns represent the 63 individual CCEC tumors (T) that were investigated in this study. Four tumors with heterogeneous histology for which the CCEC component was sequenced are marked with an asterisk (*). Frequencies of somatic mutations (% tumors mutated) and MSI are provided at left. CCEC cases are grouped according to mutation patterns (bottom), into those with mutations exclusively in serous-enriched genes (group 1: dark blue), exclusively in endometrioid-enriched genes (group 3: orange), or in both gene sets (group 2: orange and dark blue). Tumors that had no detectable alterations in this set of markers are indicated as a separate group (Other). The percentage of tumors in each group is indicated (bottom). Genes for which a subset of cases (23 tumors) were analyzed previously for mutations and MSI as reported elsewhere 7, 15, 16 are denoted by a pound sign (#).
methyltransferase, may be pathogenic loss of function mutations, based on the prevailing dogma in other solid tumors 29 and on recent observations that truncating mutations in trr, the Drosophila ortholog of MLL3/ MLL4, result in tissue overgrowth. 30 Several of our findings in CCECs and the CCEC components of mixed histology tumors are of potential clinical interest. The PIK3CA-PIK3R1-PTEN axis of the druggable PI3-Kinase pathway was mutated in 34.9% of cases. MSI was present in 11.3% of cases and is noteworthy given the clinical responses of 2 MSI EC patients to the anti-PD-1 antibody pembrolizumab in a phase 2 trial. 31 Also noteworthy is our observation that POLE exonuclease domain hotspot mutations, which are associated with a favorable outcome in EECs, were not present among the CCECs in our study; the single case (T24) that had a non-hotspot POLE exonuclease domain mutation (Phe367Leufs*15) was exome-sequenced but did not exhibit an ultramutated phenotype.
We found CCEC to be more mutationally heterogenous than SEC or EEC across a series of 7 genes (TP53, PPP2R1A, PIK3CA, PTEN, PIK3R1, ARID1A, KRAS) and MSI as evidenced by shared patterns of alterations between CCEC and SEC, and CCEC and EEC, in addition to CCEC that could not be characterized as such. Similarily, shared patterns of alteration are also observed when comparing the molecular features of CCEC in this study to those of SEC and EEC in the TCGA study. Specifically, TCGA classified SEC and EEC into 4 molecular subgroups: POLE-mutated (ultramutated), MSI (hypermutated), copy number low MSS, and copy number high (serous-like). 12 All but 1 of the SEC cases in the TCGA study were in the copy number high subgroup, and were frequently TP53-mutated, whereas EECs were distributed among the 4 subgroups. It has recently been proposed that the status of the POLE exonuclease domain, MSI, and TP53/ p53 can serve as surrogate molecular markers for this classification. 32 Our finding that 39.7% of 63 CCECs in our study were TP53-mutated and another 11.3% had MSI further demonstrates that the molecular features of CCECs are heterogeneous and overlap with those of SECs and EECs. Collectively, these observations support those of 3 smaller studies noting the molecular heterogeneity of CCEC and its similarities to SEC and EEC. 14, 17, 18 Several studies have noted considerable interobserver variability in the histologic classification of highgrade EC, including high-grade EEC, SEC, and CCEC, based on morphology alone. [33] [34] [35] [36] [37] [38] [39] For example, in a retrospective review by 11 gynecologic pathologists of 35 tumors identified from an electronic records search that included the term "clear cell" as well as "uterine" or "endometrial carcinoma," Fadare et al 36 . A limitation of our study is that we did not include a systematic pathology review of the discovery or prevalence screen tumors. Therefore, we cannot exclude the possibility that some of the molecular heterogeneity we observed may reflect inaccurate histological classification, [34] [35] [36] [37] [38] [39] a known challenge in EC pathology. However, the aim of our study was not to provide a morphologic or molecular reclassification of CCEC; rather, our findings reflect the molecular profiles of tumors from patients who were clinically diagnosed with CCEC or EC with a CCEC component.
In conclusion, we herein describe the largest exome sequencing of CCEC and a comprehensive mutational analysis of known cancer genes in this rare but clinically aggressive subtype. Our study implicates TAF1 as a novel candidate driver gene in a subset of CCECs. Moreover, our findings indicate that, on a molecular level, some cases of CCEC resemble SEC, whereas others resemble EEC. Collectively, our study sheds new insight on the mutational repertoire of CCEC. 
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